JPMorgan Chase & Co. Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price objective lifted by analysts at JPMorgan Chase & Co. from $168.00 to $200.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 20.49% from the company's previous close.

Several other equities research analysts have also commented on the stock. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $204.64.

Remove Ads

Ascendis Pharma A/S Trading Up 1.7 %

Shares of ASND stock traded up $2.75 during mid-day trading on Tuesday, reaching $165.99. The stock had a trading volume of 354,250 shares, compared to its average volume of 458,138. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The firm has a market cap of $10.07 billion, a price-to-earnings ratio of -23.38 and a beta of 0.62. The business's fifty day moving average is $141.37 and its 200-day moving average is $135.69.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $30,000. Jones Financial Companies Lllp increased its stake in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. Finally, Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.